Key Takeaways
- A 21% revenue quarter, but the real story is mix: Operating income grew 21.16% YoY as export own-brand share jumped to 57.20% from 48%, driving EBITDA margin up 1258 bps to 17.91%.
- CDMO went live with three global partners: Viatris, Manx (UK) and Arrotex (Australia) were commercialized in Q1, with management guiding ₹200–220 crore of incremental revenue from these partnerships over a period of two years.
- Margin expansion is structural, not cyclical: The end of 1.5 years of post-merger litigation expenses plus the shift to high-margin own-brand exports lifted PAT margin 827 bps to 13.26%; management says 18% EBITDA is fully sustainable, with upside to 21–22% if sales increase quarter-on-quarter.
- FY30 ambition is set: Management targets ₹1,500 crore minimum revenue and ₹200 crore+ net profit by FY30, with ₹1,200 crore by FY29 not being revised at this stage.
- What to watch next quarter: Whether Viatris volumes actually double as guided, the pace of Arrotex's Macrogol push, and any signed agreements with the two additional CDMO customers under discussion.
CDMO Commercialization & Customer Concentration
- Three partnerships went live: Viatris, Manx (UK) and Arrotex (Australia) were commercialized during Q1 FY27, marking the first quarter where contract manufacturing with global generic majors contributed at scale.
- Viatris is the anchor: The company has supplied Viatris for over 10 years, from the day export business started. Mr. Sahil Munjal's reputation with overseas customers, assisted by Mr. Varun Chhabra who moved from API export sales two years before the API sale, underpins the relationship.
- Year-one Viatris economics: Ibuprofen and Clarithromycin granules sales are expected at approximately ₹100–130 crore in year one, with the full ₹200 crore achieved over two years, by FY29.
- Volume ramp is back-loaded: Growth from Viatris molecules will reflect slowly in Q2 and Q3 FY27, with Q2 volumes expected to grow double versus Q1.
- Two more customers in the funnel: Management is actively engaged with two additional customers for the same products as the Viatris project. If cracked, this would require ₹50–75 crore of capex and generate ₹150 crore+ of revenue. Names were declined pending agreement sign-off.
- FY29 CDMO mix: The ₹1,200 crore FY29 revenue target is expected to include ₹600–650 crore of CDMO business.
Aggarwal: "We are well prepared and we are committing to our customers as and when we'll be ready for commercialization. So, the day we committed for Viatris we delivered."
Product Launches & Pipeline
- Two new products commercialized: Ibuprofen Sachet for the European market and Macrogol Sachet for UK and Australian markets launched during Q1.
- Macrogol is the next growth driver: The molecule, described as similar to Isabgol in India, is being supplied to Viatris and Arrotex in Australia with unique packaging (dry suspension and Macrogol sachets). Q2 FY27 is expected to see a major push from Arrotex on this molecule.
- Statins combination performed strongly: Ezetimibe + Atorvastatin generated approximately ₹25 crore of sales in Q1 FY27 and is expected to increase gradually every quarter.
- Clarithromycin dry suspension is expected to launch "in this year," while Esomeprazole with Viatris and Arrotex is expected to launch in FY28.
- Dossier engine is scaling: Total dossiers filed increased to 2,100+ from 1,915+, with a target of 2,500 by Q4 FY27. Global product registrations rose to 850+ from 750+.
- R&D is customer-funded by design: Management works on 5–6 molecules expected in FY27–FY29, but capex for these starts only after filings are done. The stated discipline: no R&D spend before a customer agreement is signed, and in most cases development costs are borne by the customer.
Aggarwal: "We don't want to spend a single penny in R&D before we sign off any agreement with our customers. And in most of the cases, all the development cost which we bear is borne by our customer only."
Margin Profile & Sustainability
- The 1258 bps EBITDA jump has two drivers: The shift toward high-margin own-brand exports and the end of litigation/other expenses that the formulation business had been bearing for 1.5 years post-merger.
- Management rejects the "turnaround" label: The post-merger litigation cases are now over, revealing what management calls the "real picture" rather than a cyclical recovery.
- 18% is the floor, not the ceiling: Management says 18% EBITDA margin is fully sustainable, with potential to reach 21–22% if sales increase quarter-on-quarter.
- Margin timing is deliberately conservative: Internally, management plans to increase EBITDA margins from 18% after Q2, but publicly commits only to Q3, saying it does not want to commit so early.
- Product selection enforces margin discipline: The starting point for any product selection is a minimum 50–55% gross margin.
Aggarwal: "Yes, 18% is fully sustainable and we plan if the sales we are able to increase quarter-on-quarter they might go up to 21 to 22%."
Export Mix & Revenue Composition
- Export own-brand share jumped to 57.20% of quarterly sales from 48% YoY, driven by deeper own-brand penetration in export markets. This mix shift was the key driver of margin profile expansion.
- Domestic segments declined proportionally: Branded generics, ethical division and contract manufacturing all fell as a share of sales YoY, while continuing to provide a stable cash generation base.
- The export growth engine: The major export push came from the newly launched molecule Ezetimibe + Atorvastatin supplied in Europe.
- No seasonality in exports: Export turnover has no seasonal impact; domestic sales are a little bit seasonal.
- FY27 export expectation: Management expects ₹750 crore of export sales this year, with approximately 45% through CDMO business.
- FY27 revenue target: Management expects ₹900 crore this year, and may achieve targets early if capacity expansion completes well in advance, possibly one year early.
Capacity, Capex & Infrastructure
- ₹250 crore cash deployment plan: Cash on books will be gradually deployed in the business over 2.5 years, primarily in capex.
- Three capex streams are already kick-started: Warehouse, capacity enhancement at the existing facility, and the Jammu division.
- Warehouse relocation unlocks production space: A new warehouse near factory premises will free production facility space to enhance production of existing molecules.
- Samba facility upgrade underway: The planned upgrade to EU-GMP and PIC/S standards is progressing as planned, expected to enhance export capabilities and support product filings across regulated markets.
- Capacity utilisation is annual, not quarterly: Management works on capacity utilisation on an annual basis only; when pressed, they provided approximately 70% for Ibuprofen and granules.
- FY29 plan represents 90% of capacity used over time, with no dearth of capacity expected.
- New R&D facility planned: R&D is currently in Panchkula; new land has been bought for a new R&D facility, currently handling regulatory compliance, tech transfer and global filings.
Synthimed Stake & API Divestment Legacy
- The API exit was a deleveraging decision: Both Ind-Swift Limited (parent, 1986) and Ind-Swift Laboratories (API company, 1996) had high leverage; both admitted to CDR in 2012 and again in 2014; Ind-Swift Limited's CDR failed in 2015; ARCs came in and debts were sold; the entire debt was settled in 2018 via Edelweiss fund borrowing. The decision was made to exit the API business because debts were too high to repay through running the businesses.
- The sale process was not smooth: The deal was first signed with PI Industries but fell off at payment time; it was then discussed with Synthimed (erstwhile India Resurgent Fund) and sold in FY24.
- No divestment plans this year: Management wants to hold the Synthimed stake for a longer period, and did not provide a valuation figure for the 7.8% stake.
- Tag-along right exists: Whenever the PE investor exits Synthimed, Ind-Swift has a tag-along right. Management did not directly confirm whether they would exercise it.
- Synthimed is performing: The company is on track to achieve budgeted EBITDA of approximately ₹750-odd crore this year.
Aggarwal: "The decision was very clear that API business is doing good, we should exit that API business, get value, make the group debt-free."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CDMO incremental revenue | ₹200–220 crore from CDMO partnerships | FY27 |
| Viatris year-one sales | ₹100–130 crore from Ibuprofen and Clarithromycin granules | Year one (FY27) |
| Full CDMO revenue from Viatris project | ₹200 crore | By FY29 |
| Viatris volume growth | Q2 volumes double versus Q1 | Q2 FY27 |
| Arrotex Macrogol push | Major push on Macrogol molecule | Q2 FY27 |
| Ibuprofen and Clarithromycin granules progress | Progress from these molecules | Q3 and Q4 FY27 |
| EBITDA margin increase | Increase from 18% | Q3 FY27 (internal plan: Q2) |
| FY27 revenue | ₹900 crore | FY27 |
| FY27 export sales | ₹750 crore, ~45% via CDMO | FY27 |
| Dossier count | 2,500 dossiers | Q4 FY27 |
| FY29 revenue | ₹1,200 crore, including ₹600–650 crore CDMO | FY29 |
| FY30 vision | Minimum ₹1,500 crore revenue, ₹200 crore+ net profit | FY30 |
| Cash deployment | ₹250 crore deployed in business, primarily capex | 2.5 years |
| Capex for two additional CDMO customers | ₹50–75 crore, revenue ₹150 crore+ | If agreements signed |
| Clarithromycin dry suspension launch | Launch | "In this year" |
| Esomeprazole launch (Viatris, Arrotex) | Launch | FY28 |
| Medium-term growth | 20–25% CAGR with EBITDA margins above 18% | Beyond FY27 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Operating income | ₹186.08 cr, up 21.16% YoY from ₹153.58 cr |
| Operating EBITDA | ₹33.32 cr, up 2.85x YoY from ₹8.66 cr |
| Operating EBITDA margin | 17.91%, up 1258 bps YoY from 5.33% |
| PAT excluding exceptional item | ₹24.68 cr, up 2.04x YoY from ₹8.12 cr |
| PAT margin | 13.26%, up 827 bps YoY from 4.99% |
| Export own-brands share of sales | 57.20%, up from 48% in Q1 FY26 |
| Export contract manufacturing share of sales | 26.64%, down from 29% in Q1 FY26 |
| Domestic branded generics share of sales | 6.41%, down from 10% in Q1 FY26 |
| Domestic ethical division share of sales | 6.14%, down from 7% in Q1 FY26 |
| Domestic contract manufacturing share of sales | 3.61%, down from 6% in Q1 FY26 |
| Export gross margin | ~55% |
| Viatris CDMO sales in Q1 | ₹5–6 cr from Ibuprofen and Clarithromycin granules |
| Ezetimibe + Atorvastatin Q1 sales | ~₹25 cr |
| FY27 expected export sales | ₹750 cr, with ~45% from CDMO |
| FY27 expected revenue | ₹900 cr |
| FY29 revenue guidance | ₹1,200 cr |
| FY30 revenue target | ₹1,500 cr minimum, net profit ₹200 cr plus |
| Total dossiers filed | 2,100+, up from 1,915+ |
| Global product registrations | 850+, up from 750+ |
| Dossier target by Q4 FY27 | 2,500 |
| Capacity utilisation in Q1 | ~70% for Ibuprofen and granules |
| Planned capex over 2–2.5 years | ₹250 cr, split across warehouse, capacity enhancement, and Jammu division |
| Synthimed budgeted EBITDA for FY27 | ~₹750-odd cr |